Published in Drug Week, May 26th, 2006
The phase I trials, conducted in the U.S. and in Europe, were designed to assess the safety and pharmacology of ALN-RSV01 in healthy volunteers.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.